Conditional loss of TGF-β signalling leads to increased susceptibility to gastrointestinal carcinogenesis in mice
Authors: Hahm, K-B.1; Lee, K. M.1; Kim, Y. B.1; Hong, W. S.2; Lee, W. H.1; Han, S. U.1; Kim, M. W.1; Ahn, B. O.3; Oh, T. Y.3; Lee, M. H.1; Green, J.4; Kim, S. J.4
Source: Alimentary Pharmacology & Therapeutics, Volume 16, Supplement 2, April 2002 , pp. 115-127(13)
Publisher: Blackwell Publishing
Abstract:
Background: Downregulation of TGF-β receptors is implicated in colon cancer development. Inactivation of either of the two transmembrane serine/threonine kinases, TGF-β1 types I/II receptors, is now implicated in carcinogenesis, especially gastrointestinal carcinogenesis. Methods: We generated transgenic mice, called pS2-dnRII or ITF-dnRII, of which the dominant negative mutant of the TGF-β type II receptor was expressed under the control of tissue-specific promoters, the pS2 promoter for stomach and ITF for intestine. They were either infected with H.pylori (ATCC 43504 strain, CagA+ and VacA+) or administered with azoxymethane to determine the significance of loss of TGF-β signalling in gastrointestinal carcinogenesis. Results: Gastric adenocarcinoma developed in pS2-dnRII mice, whereas only chronic active gastritis was noted in wild-type littermates after 36 weeks of H.pylori infection. Mice lacking in TGF-β signalling specifically in the stomach showed a significantly higher proliferation cell nuclear antigen-labelling index when infected with H.pylori than wild-type littermates (P < 0.01). Development of colonic aberrant crypt foci was provoked in mice by intraperitoneal injections of azoxymethane, and ITF-dnRII mice showed significantly higher incidences of ACF and colon cancers than wild-type littermates. Conclusions: Maintaining normal TGF-β signalling in the gastrointestinal tract seems to be important either for preventing abnormal mucosal proliferation, or for suppressing or retarding carcinogenesis.Document Type: Research article
DOI: 10.1046/j.1365-2036.16.s2.3.x
Affiliations: 1: Ajou Helicobacter Research Group, Ajou University School of Medicine, Suwon, Korea, 2: Asan Medical Center, Ulsan University School of Medicine, Seoul, Korea, 3: Dong-A Pharmaceutical Research Institute, Yongin, Korea, 4: Laboratory of Cell Regulation and Carcinogenesis, NCI, Bethesda, MD, USA

Click here for Page Help